A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase III
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Bendamustine (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors SymBio Pharmaceuticals
- 15 Jan 2018 According to a SymBio Pharmaceuticals media release, first patient has been enrolled.
- 05 Sep 2017 According to a SymBio Pharmaceuticals media release, company plans to file an NDA for relapsed/refractory diffuse large B-cell lymphomain the 2nd half of 2019.
- 05 Sep 2017 New trial record